Previous Article | Next Article ![]()
Journal of Clinical Microbiology, January 2001, p. 375-376, Vol. 39, No. 1
Victorian Infectious Diseases Reference
Laboratory, North Melbourne, Victoria, Australia
Received 13 July 2000/Returned for modification 13 September
2000/Accepted 23 October 2000
At various times postonset of rash, 74 patients positive for
measles virus-specific immunoglobulin M provided samples for detection
of measles virus RNA by a reverse transcriptase PCR. Of lymphocytes,
urine, throat swab, and serum specimens, throat swab specimens were
optimal for detection of measles virus RNA during the first 2 weeks
after the rash.
Detection of measles virus RNA by
reverse transcriptase (RT) PCR (RT-PCR) from various clinical
specimens, including throat swab (TS), nasopharyngeal aspirate,
urine, cerebrospinal fluid, and blood specimens, has been described by
several groups (7, 8, 10). However, to our knowledge,
no investigation of optimal specimen type or sampling time for
maximization of the chance of measles virus RNA recovery has been
reported. Identification of the optimal specimen type and sampling time
for the detection of measles virus RNA will enhance the rapid
confirmation of true measles virus infections and the identification of
measles virus genotypes for molecular epidemiological studies.
A measles outbreak in the state of Victoria in Australia in 1999 (6) provided the opportunity to collect clinical material from naturally infected individuals. In addition to clinical
information, plain blood for serum, blood containing EDTA for recovery
of peripheral blood leukocytes (PBLs), urine, and TS samples were
collected as part of the enhanced measles surveillance system
(5). TS samples were collected with a sterile dry swab
from the back of the throat. The swab tip was placed in 3 ml of sterile
viral transport medium and was transported to the laboratory at 4°C.
On the day of collection these samples were stored at 4°C and
analyzed by RT-PCR within 1 week. Serum was tested for the presence of
measles virus-specific immunoglobulin M (IgM) and IgG antibodies by a commercial enzyme immunoassay (Dade Behring Enzygnost, Marburg, Germany). All sera were tested for the presence of IgM and IgG antibodies to human parvovirus B19 (Biotrin, Dublin, Ireland) and
rubella virus (Beckman Access, Chaska, Minn.). All sera were positive
for measles virus-specific IgM and negative for parvovirus B19- and
rubella virus-specific IgM. Total RNA was extracted directly from 100 µl of the clinical specimen by a guanidinium isothiocyanate technique
(2). Following reverse transcription of RNA with random
primers and avian myeloblastosis virus RT, specific primers targeted to
the nucleoprotein gene of the measles virus Edmonston strain were used
in a heminested RT-PCR to amplify a 528-bp measles virus-specific
fragment (1). Statistical analysis was performed with
Stata statistical software (release 6.0; Stata Corporation, College
Station, Tex.). A 95% confidence interval (CI) for the proportion of
positive samples for each specimen type was calculated by using the
binomial distribution. Tests for association were performed by
chi-square or Fisher's exact test, as appropriate. Multiple-comparison
testing was used to investigate differences in proportions between
specimen types.
A total of 249 samples collected from 74 patients with confirmed
measles were available for RT-PCR analysis. Not all patients provided
all four specimen types. Thirty-six patients provided at least one
sample each of PBLs, urine, TS, and serum. The TS sample was the only
positive sample in six of these patients, whereas in two patients each
the urine or PBL sample was the only positive sample. Table
1 shows the proportion (with 95% CI) of measles virus RNA-positive samples for each specimen type according to
days postonset of the rash (day of rash onset = day 0). Overall, at least one RT-PCR-positive sample was obtained from 48 of the 74 (65%) measles virus-specific IgM-positive patients. Measles virus RNA
was recovered from a high proportion of TS, urine, and PBL samples
compared to the proportion of serum samples from which it was recovered
in the first 3 days after rash onset. Only the difference between TS
and serum samples approached significance (P = 0.054).
Between days 4 and 7, measles virus RNA was detected in TS and urine
samples significantly more often than in serum samples (P = 0.002 and 0.032, respectively), but there was no significant
difference in RT-PCR detection rates between PBL, urine, and TS
samples.
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.1.375-376.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Investigation of Optimal Specimen Type and Sampling
Time for Detection of Measles Virus RNA during a Measles
Epidemic
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
TABLE 1.
Analysis of measles virus RT-PCR positivity with clinical
samples according to days postonset of rash (70 patients) or other
clinical symptoms (4 patients)
During the second week after onset of rash, TS and PBL samples yielded a higher proportion of measles virus RNA-positive samples than urine samples, although no difference between specimen type reached significance. Fourteen days or more after the onset of a rash, the rate of RNA detection for all specimen types was significantly lower than that of the first 14 days (14 versus 43% [P < 0.001]) but was not significantly different between PBL, urine, and TS samples. When comparing specimen types for all samples collected during the outbreak, only TS samples remained significantly more likely than serum samples to be RT-PCR positive (P = 0.005).
Serum samples were significantly more likely to be RNA positive before the appearance of an IgG response. Prior to the appearance of IgG, 23 of 56 (41%) serum samples were positive for measles virus RNA. However, only 2 of 47 (4%) serum samples were positive once specific IgG was present (P < 0.001). A 1992 study has suggested that measles virus viremia may be prolonged in patients with more severe disease (3). Twenty-eight of the 74 patients with confirmed cases (38%) were hospitalized, and our results suggest that disease severity, using hospitalization as a surrogate marker for severe disease, was not associated with an increased rate of detection of viral RNA by RT-PCR (P = 0.8).
Diagnosis of acute measles virus infection based on clinical presentation may have a positive predictive value as low as 5% during nonepidemic periods (5), and in low-prevalence countries, laboratory confirmation by IgM serology is important. RT-PCR provides a rapid and sensitive method for the detection of measles virus RNA from a variety of clinical specimens (4, 7-10) and plays an important supporting role in measles diagnosis. In our hands, the measles virus RT-PCR is 1,000-fold more sensitive than virus isolation in B95a cells (data not shown). We have found RT-PCR for measles virus to be useful for clarification and confirmation of measles virus infection in a variety of circumstances, including atypical or complicated clinical presentations, cases in which IgM reactivity to multiple viruses is present, and cases in which serum for antibody testing is not available. Combined with sequencing, RT-PCR facilitates identification of measles virus genotypes (1) and differentiation between vaccine-associated and wild-type measles virus infection (4).
We conclude that a TS sample is the preferred specimen for the detection of measles virus RNA by RT-PCR. Collection of multiple specimens does not enhance the recovery rate sufficiently to justify this as routine practice. In cases in which serum collected before development of a measles virus IgG antibody response is the only specimen available, RT-PCR may be worth attempting. While the sample size in this study was too small for most relative differences in recovery rate between specimens to reach significance, it is unlikely that a sufficiently large set of high-quality specimens could be collected in countries with high measles vaccination rates. The current study is therefore likely to provide the best indication of optimal specimen types for the recovery of measles virus RNA.
| |
ACKNOWLEDGMENTS |
|---|
We thank Stephen Lambert Department for Human Services, Melbourne, Victoria, Australia, for clinical data, Debbie Gercovich for collection of samples, Jennie Leydon for serology testing, and Graham Byrnes for statistical advice.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Epidemiology and Public Health Division, Victorian Infectious Diseases Reference Laboratory, 10 Wreckyn St., North Melbourne 3051, Victoria, Australia. Phone: 61 3 9342 2686. Fax: 61 3 9342 2665. E-mail: michaela.riddell{at}mh.org.au.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Chibo, D.,
C. J. Birch,
P. A. Rota, and M. G. Catton.
2000.
Molecular characterization of measles viruses isolated in Victoria, Australia, between 1973 and 1998.
J. Gen. Virol.
81:2511-2518 |
| 2. | Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159[Medline]. |
| 3. | Forthal, D. N., S. Aarnaes, J. Blanding, L. de la Maza, and J. G. Tilles. 1992. Degree and length of viremia in adults with measles. J. Infect. Dis. 166:421-424[Medline]. |
| 4. | Jenkin, G. A., D. Chibo, H. A. Kelly, P. A. Lynch, and M. G. Catton. 1999. What is the cause of a rash after measles-mumps-rubella vaccination? Med. J. Aust. 171:194-195[Medline]. |
| 5. | Lambert, S., H. Kelly, R. Andrews, M. Catton, P. Lynch, J. Leydon, D. Gercovich, G. Hogg, M. Morgan, and R. Lester. 2000. Enhanced measles surveillance during an interepidemic period in Victoria. Med. J. Aust. 172:114-118[Medline]. |
| 6. |
Lambert, S.,
P. Lynch,
M. Morgan,
D. Gercovich,
H. Kelly,
M. Riddell,
J. Leydon, and M. Catton.
1999.
Measles outbreak young adults at high risk.
Victorian Infect. Dis. Bull.
2:21-22. (Available online [http://www.dhs.vic.gov.au/phd/vidb/].)
|
| 7. | Matsuzono, Y., M. Narita, N. Ishiguro, and T. Togashi. 1994. Detection of measles virus from clinical samples using the polymerase chain reaction. Arch. Pediatr. Adolesc. Med. 148:289-293[Abstract]. |
| 8. | Nakayama, T., T. Mori, S. Yamaguchi, S. Sonoda, S. Asamura, R. Yamashita, Y. Takeuchi, and T. Urano. 1995. Detection of measles virus genome directly from clinical samples by reverse transcriptase-polymerase chain reaction and genetic variability. Virus Res. 35:1-16[CrossRef][Medline]. |
| 9. | Rota, P. A., A. S. Khan, E. Durigon, T. Yuran, Y. S. Villamarzo, and W. J. Bellini. 1995. Detection of measles virus RNA in urine specimens from vaccine recipients. J. Clin. Microbiol. 33:2485-8[Abstract]. |
| 10. |
Shimizu, H.,
C. A. McCarthy,
M. F. Smaron, and J. C. Burns.
1993.
Polymerase chain reaction for detection of measles virus in clinical samples.
J. Clin. Microbiol.
31:1034-9 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|